Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia.

Abstract

Initial treatment with androgen (metenolone acetate) alone for 19 weeks had no effect in a 45-year-old Japanese female with refractory anemia (RA). The patient achieved trilineage hematologic recovery after addition of recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human erythropoietin (Epo) to the androgen therapy. Anemia progressed after the cessation of metanolone acetate, but was effectively treated by the readministration of metenolone acetate. Thus, the androgen therapy in combination with hematopoietic growth factors such as G-CSF and/or Epo may be effective in patients with RA.

• Authors: Y Katayama, K Kojima, E Omoto, M Harada
• Journal: International journal of hematology (Int J Hematol) Vol. 65 Issue 1 Pg. 89-92 (Dec 1996) ISSN: 0925-5710 [Print] Japan
• PMID: 8990630 (Publication Type: Case Reports, Journal Article)

Chemical References

• Recombinant Proteins
• Erythropoietin
• Granulocyte Colony-Stimulating Factor
• Methenolone
• methenolone acetate

Topics

• Anemia, Refractory (drug therapy)
• Drug Therapy, Combination
• Erythropoietin (therapeutic use)
• Female
• Granulocyte Colony-Stimulating Factor (therapeutic use)
• Humans
• Methenolone (analogs & derivatives, therapeutic use)
• Middle Aged
• Recombinant Proteins